PLUS THERAPEUTICS, Inc. (PSTV): Price and Financial Metrics


PLUS THERAPEUTICS, Inc. (PSTV): $0.74

-0.11 (-12.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PSTV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PSTV Stock Price Chart Interactive Chart >

Price chart for PSTV

PSTV Price/Volume Stats

Current price $0.74 52-week high $2.30
Prev. close $0.85 52-week low $0.39
Day low $0.67 Volume 6,650,337
Day high $0.80 Avg. volume 2,600,088
50-day MA $0.54 Dividend yield N/A
200-day MA $0.90 Market Cap 16.70M

PLUS THERAPEUTICS, Inc. (PSTV) Company Bio


PLUS THERAPEUTICS, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops, and commercializes specialty novel therapeutics for the treatment of cancer and other life-threatening diseases. PLUS THERAPEUTICS operates in the States of Texas and California.


PSTV Latest News Stream


Event/Time News Detail
Loading, please wait...

PSTV Latest Social Stream


Loading social stream, please wait...

View Full PSTV Social Stream

Latest PSTV News From Around the Web

Below are the latest news stories about Plus Therapeutics Inc that investors may wish to consider to help them evaluate PSTV as an investment opportunity.

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2021 Results - Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) Q4 2021 Earnings Conference Call February 24, 2022, 05:00 PM ET Company Participants Marc Hedrick - President & CEO Norman LaFrance - Chief Medical Officer Andrew Sims - CFO Conference Call Participants Jianing Li - Maxim Group Sean Lee - H.C. Wainwright Ed Woo - Ascendiant...

SA Transcripts on Seeking Alpha | February 25, 2022

Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Expanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM Phase 1 clinical trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the f

Yahoo | February 24, 2022

Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial

Initial plan to evaluate project feasibility, may lead to expanded partnership for clinical and regulatory implementationAUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced a partnership with Medidata, a Dassault Systèmes company, to evaluate the use of its Synthetic Control Arm® (SCA) solution in a

Yahoo | February 22, 2022

Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022

AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial

Yahoo | February 18, 2022

Plus Therapeutics to Present at BIO CEO & Investor Conference

AUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Monday, February 14, 2022 at 1:15 p.m. ET, at the New York Marriott Marquis. The Comp

Yahoo | February 7, 2022

Read More 'PSTV' Stories Here

PSTV Price Returns

1-mo 50.04%
3-mo 39.52%
6-mo -27.45%
1-year -61.66%
3-year -89.43%
5-year -99.54%
YTD -29.52%
2021 -48.02%
2020 -15.83%
2019 -83.45%
2018 -90.33%
2017 -80.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4482 seconds.